All work performed at Weill Cornell Medical College and University of Queensland.
Error and Bias in the Evaluation of Prescription Opioid Misuse: Should the FDA Regulate Clinical Assessment Tools?
Version of Record online: 17 APR 2013
Wiley Periodicals, Inc
Volume 14, Issue 7, pages 982–987, July 2013
How to Cite
Meltzer, E. C., Hall, W. D. and Fins, J. J. (2013), Error and Bias in the Evaluation of Prescription Opioid Misuse: Should the FDA Regulate Clinical Assessment Tools?. Pain Medicine, 14: 982–987. doi: 10.1111/pme.12099
Disclosures: No funding sources were provided and no conflicts of interest exist.
- Issue online: 15 JUL 2013
- Version of Record online: 17 APR 2013
- Clinical Assessment Tool;
- Prescription Opioid Monitoring;
- Diagnosing Prescription Opioid Addiction;
- Federal Regulation
Clinicians who prescribe chronic opioid therapy are concerned about identifying patients who are at-risk for misusing, abusing, or diverting (i.e. selling) their pain medications. Experts have specifically recommended using clinical assessment tools as part of a comprehensive plan for mitigating opioid-related risks. These tools are typically short, standardized questionnaires that screen for the presence or absence of putatively aberrant medication-related behaviors thought to be predictive of addiction. Interestingly, these tools remain wholly unregulated by the Food and Drug Administration (FDA) or other authorities.
This paper reviews how these instruments are used and the normative assumptions informing their use, fully appreciating that these screening tools do not have the power to diagnose illness or an addiction disorder.
We conclude that these clinical assessment tools should be regulated because, as we will argue, any screening tool that can assess patients for the potential for opioid-related aberrant behaviors are powerful instruments that merit additional scrutiny and oversight—perhaps by the FDA and other regulatory agencies.